Chinese Medicine Neuroaid Efficacy on Stroke Recovery

Aug 11 2013

A Double-Blind, Placebo-Controlled, Randomized Study, revealed that MLC601 is statistically no better than placebo in improving outcomes at 3 months

when used among patients with acute ischemic stroke of intermediate severity. The trail suggested that longer treatment duration and follow-up of participants with treatment initiated after 48 hours may be considered in future studies.

the paper was published in stroke journal August 2013. please click here to review the abstract